IMA Accepted The Start Of Community Transmission In India: COVID-19

On Saturday, the IMA said that the coronavirus situation in India is really bad. The IMA further added that community transmission has started in India as the infection is also spreading in rural areas.

While talking to ANI, Dr VK Monga who is a Chairman of IMA Hospital Board of India said that India was facing exponential growth in coronavirus infection as each day 30,000 fresh cases are seen. “This is a really bad situation for the country,” he said. “There are so many factors connected with it but overall it is now spreading to rural areas. This is a bad sign.”

He further warned that containment of coronavirus in towns and villages will be difficult for the government. “In Delhi, we were able to contain it, but what about interior parts of the country in Maharashtra, Kerala, Goa, Madhya Pradesh?” He added that the state governments need to coordinate with the Centre to manage the worsening health crisis.

Earlier, the Union Health Ministry has constantly denied community transmission in India. However, on Friday, Pinarayi Vijayan who is the CM of Kerala accepted that some parts of Thiruvanthapuram have started facing community transmission. Thiruvanthapuram has been divided into three critical containment zones and they are put under lockdown for 10 days.

He also added that the only way to stop the pandemic is the vaccine or herd immunity. “There have to be phases of trials and human trials, the efficacy and side effects,” he said. “Also it is important to see how long this immunity will last because most of the patients are unable to go beyond three months of immunity.”

At present India is working on two vaccines. Recently, AIIMS approved for the human trials of Covaxin. Covaxin is the first indigenous vaccine against the coronavirus. From Monday AIIMS will start the enrolling of volunteers for the trial. Second Indian vaccine belongs to a Gujarat based pharmaceutical giant Zydus Cadila’s ZyCoV. Earlier this week it also started the stage of human trials.

Source

Facebook Comments
Aisha Zainab: